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Introduction
Acronyms: UC-ulcerative colitis IBD-inflamitory bowel disease
Ulcerative colitis (UC), a subdivision of inflammatory bowel 
disease (IBD), affects 1 to 2 million people in the United 
States each year. The reason for ulcerative colitis is not quite 
understood. However, the condition appears to be related to 
a combination of genetic and environmental factors. Minor 
symptoms include unformed stools, abdominal cramping, and 
diarrhea (Lichteger et al.,1994). As the severity of the disease 
increases, patients experience fatigue, loss of appetite, weight 
loss mucus present in the stool, intense rectal bleeding in 
addition to fever and anemia. UC can ensue at any time yet it is 
usually diagnosed in a person’s teenage years.  Roughly around 
20% of people with UC have a close relative with IBD.  (CCFA.
org, 2015).
UC is normally a lifelong chronic illness with times of intense 
flairs and remission. A severe attack which can be a potential-
ly fatal condition, is sometimes the first manifestation and is 
observed in about 15% of the patients with this disease. The 
introduction of corticosteroids sharply reduced the death rate. 
Corticosteroids remain as a pillar in the treatment of a severe 
attack of ulcerative colitis. The importance of achieving remis-
sion is undermined by the fact that the long-term colectomy 
rate in patients with a severe attack who achieve clinical and 
endoscopic remission after steroids is similar to those with a 
moderately severe or mild attack.  The dependence on corti-
costeroid is a continuous problem. Steroid dependent patients 
may develop osteoporosis as they get older, in addition to deal-
ing with weight gain, moon face, increase in appetite, as well as, 
acne and joint pain. Furthermore, the likelihood of a colectomy 
within the first five years from diagnosis ranges from  9% in pa-
tients with distal colitis to 35% in patients with complete colitis, 
normally because of unsuccessful medical therapy. The risk of 
recurring inflammatory bowel disease in the form of pouchitis 
ranges from 15.5% 1 year after the procedure to 45.5% 10 years 
after the procedure.  Accordingly, new treatments for ulcerative 
colitis are needed (CCFA.org, 2015).
In recent years biological therapy has been the new method of 
treatment for those who are steroid dependent and or failing 
to respond to other treatments. Tumor necrosis factor α (TNF-
α) is a key pro-inflammatory cytokine in patients with Crohn’s 
disease, but is also found in amplified amounts in the intestinal 
tissue, stools, blood and urine of patients with ulcerative coli-
tis.  Infliximab, also known as Remicade, is an IgG1 monoclonal 
antibody that binds with intense strength to TNF-α, neutralizing 
its biologic activity (Simmons & Jewell, 2002). The question now 
becomes; will biological therapy be the answer to help induce 
clinical remission in those suffering from UC? 
Material and methods
In order to answer the question proposed above, many re-
search articles with relation to this topic have been read. Touro 
College’s library database, the national website of Pubmed and 
Google Scholar were all used to obtain information for this 
paper. All of the articles and information that was accumulated 
through this research have been used in an attempt to conclu-
sively determine if biological therapy will induce a remission in 
patients living with active state of ulcerative colitis.
Different types of ulcerative colitis
The symptoms present for a person with ulcerative colitis will 
vary based on the amount and severity of inflammation present 
and the site of the disease in the large intestines. Ulcerative 
proctitis, the mildest form of ulcerative colitis, is limited to the 
rectum (about 6 inches or less).  Proctosigmoiditis is colitis that 
affects the rectum and sigmoid colon-which is located superior 
to the rectum. Proctosigmoiditis can be determined sometimes 
by the symptom of tenesmus (straining to have a bowel move-
ment.)  In addition, moderate pain on the lower left side of 
the abdomen may occur while the disease is present. The third 
version of colitis is known as left sided colitis. This presents as 
continuous inflammation that begins at the rectum and goes 
up as far as the splenic flexure (a bend in the colon near the 
spleen in the upper left abdomen). Symptoms for left side colitis 
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include severe pain on the left side of the abdomen,  in addition 
to loss of appetite. Lastly, the most severe form of ulcerative 
colitis is pancolitis. Pancolitis affects the entire colon causing 
terrible abdominal pain, weight loss and complete loss of appe-
tite (CCFA.org, 2015).
Climbing the medical ladder
Today, there are very effective treatments on the market to help 
control the disease with the goal of putting it into remission. The 
main aim of the different treatments is designed to decrease in-
flammation. This not only allows the colon to heal, but also re-
lieves the symptoms of diarrhea, rectal bleeding and abdominal 
pain accompanied by the flare. Unfortunately, there is no “one size 
fits all” treatment plan for everyone suffering with this disease. 
One person may do just fine with the most minor suppository 
and live fine the rest of his life, while another may require more 
invasive treatment or need a complete colectomy. Therefore, the 
approach must be customized for each individual person because 
each person’s disease is different. With the correct medical treat-
ment, a patient can achieve remission with the hope of  the state 
of remission lasting for months or even years.  Nonetheless, ul-
cerative colitis may flare up at times from the reappearance of 
inflammation or from a specific trigger. Reoccurrence of a flare 
usually indicates the need to change the medication regimen for 
the patient. The choice of drugs to treat a patient is dependent 
upon the severity of the disease.  The most commonly prescribed 
drugs fall into three basic categories:
Aminosalicylates: This class of drugs encompass 5-aminosa-
licylic acid commonly known as the 5-ASA . This class of drug 
is available in an oral form in addition to a suppository or an 
enema. The goal of the 5-ASA is to line the GI tract with the 
hope to decrease inflammation. In addition, Aminosalicylates are 
beneficial as a maintenance treatment in order to prevent a re-
lapse of the disease (Colombel et al., 2010).
Corticosteroids: The job of steroids is to prevent the body 
from launching an inflammatory cascade. Additionally, cortico-
steroids work to keep the immune system properly balanced. 
Steroids are effective for short-term control of flare-ups. This 
class of drugs is known to help “put out the fire”. Yet, corti-
costeroids are not recommended for long term use or as a 
maintenance drug for UC because of their tremendous amount 
of side effects. The goal of steroids is to buy the patient time, 
not fix the problem.  A person who is unable to come off ste-
roids without experiencing a relapse of the disease will then be 
prescribed a higher class of drugs to help manage the disease 
(Colombel et al., 2010). 
Immunomodulators: Immunosuppressants work to con-
trol the body’s immune system response in order to prevent 
ongoing inflammation. Immunomodulators are mostly used in 
people who have failed to respond to the 5-ASA and steroids 
have not been effective or have been minimally effective in 
controlling the disease. Furthermore, immunosuppressants are 
geared to allow people who are steroid dependent to eliminate 
the use of them (Sood et al., 2002). 
Though these three possibilities of treatments have been shown 
to be effective, there are always patients who fail to respond to 
the three treatment options. These patients were left with no 
choice but to have surgery to rid them of the disease leaving 
them without a colon and remaining with a pouch for the rest 
of their lives. It had become evident that there was a need to 
help prevent patients from undergoing a complete colectomy.
TNF-a and inflammation
All humans have a large gastrointestinal mucosal surface that 
is continually being exposed to billions of potentially harmful 
antigens from our food, bacteria and the environment. However, 
the mucosal surface of the GI tract possesses an immune sys-
tem that strongly controls the balance between immunogenic 
responsiveness and non-responsiveness-tolerance. Response to 
luminal antigens provokes “controlled” inflammation that is rap-
idly down regulated after eradication of the pathogen. However, 
this is not the case for someone with ulcerative colitis. In this 
disease this state of equilibrium is disturbed resulting in a state 
of chronic inflammation. During the start of the inflammation, 
antigen presenting cells, such as macrophages, cause the acti-
vation of T lymphocytes. T lymphocyte cells divide into two T 
helper T1 and T2 cells. T1 cells secrete interferon gamma (IFNy) 
which then enables macrophages to produces TNFa (Simmons 
& Jewell, 2002). 
 TNFa is an inflammatory mechanism that has been shown to 
play a vital role in the pathogenesis of IBD. The transcribing of 
the TNFa gene in stimulated macrophages, platelets, mono-
cytes, adipocytes and T cells results in the secretion of TNFa. 
Circulating TNFa binds to 2 TNFa receptors facilitating numer-
ous biological effects including activation of other macrophages, 
further expansion of the T cell response, and initiation of granu-
loma formation. TNFa also lengthens inflammation by triggering 
NF-kB dependent pathways, which contribute to ulceration and 
degradation of the mucosa through the release of MMP (matrix 
metalloproteins). TNFa triggers other inflammatory mediators, 
such as, IL6 therefore strengthening the early sequence of the 
inflammatory cascade. Increased TNFa production and NFKb 
have been shown to be abundant in lamina propria mononucle-
ar cells derived from UC patients with ulcerative colitis through 
stool, urine and blood tests (Hassan et al., 2007).
Recent advancement in bio-technology have thankfully led to 
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the development of a large array of new therapeutic agents 
intended to target the exact site in the multifaceted cascade 
of cytokine and chemokine effector molecules involved in UC 
pathogenesis. In particular, the introduction of the chimeric 
monoclonal antibody to TNFa has deeply affected the clinical 
treatment of moderate to severe ulcerative colitis, opening the 
door to a new era in the treatment of this disease. 
Infliximab
Infliximab is the first and most widely studied biological agent 
for ulcerative colitis.  As of 2006, Infliximab has been approved 
by the FDA for the treatment of ulcerative colitis. “This bio-
logic is a chimeric monoclonal antibody to TNFa composed 
of a “human” IgGI constant region (75%) and murine-derived 
antigen binding variable region (25%)” (Sands & Kaplan, 2007 
). Infliximab is able to bind powerfully to both soluble and 
membrane-bound TNFa receptors.  The actual mechanism of 
Infliximab is not completely understood, direct neutralization 
of TNFa does not entirely explain its effect. Infliximab has 
been found to apply a proapoptotic effect on monocytes and 
T cells in the lamina propria of the gut. The proapoptotic ef-
fect in infliximab may be exerted, preventing the production of 
granulocyte macrophage colony-stimulating factor, which is a 
growth factor that stimulates granulocyte growth and differen-
tiation and activates neutrophils with greater adhesion (Sands 
& Kaplan, 2007).  
Patients were eager to try this treatment option hoping to get 
their disease under control. A study was conducted in March 
2002 testing the safety and efficacy of Infliximab.  This study 
consisted of two large double-blind, placebo controlled trials 
known as the Active Ulcerative Colitis Trials 1 and 2 (ACT 1 
and ACT 2). Both trails were done on 364 patients with mod-
erate to severe ulcerative colitis. All participants in ACT 1 who 
were considered eligible were screened for a confirmed diag-
nosis of ulcerative colitis via biopsy and endoscopies. Eligible 
patients had active colitis with a Mayo score of 6 to 12 points 
(scores range from 0-12 with higher scores indicating more 
severe disease activity).  Additionally, eligible patients also had 
active disease on the sigmoidoscopy exam results (despite si-
multaneous treatment with steroids alone or in combination 
with immunosuppressant’s, aza or 6mp). ACT 2 allowed study 
participants who had only failed 5 ASA’s to participate. Patients 
formerly exposed to infliximab or any other anti-TNF agents 
were omitted. Patients who were eligible were randomly as-
signed to be administered intravenous infusions or infliximab 
at a dose of 5mg or 10mg per kilogram of weight or a placebo 
at weeks 0, 2, and 6 and then every 8 weeks. Patients were 
monitored through week 54 in ACT 1 and week 30 in ACT 2 
(Rutgeerts et al., 2005). 
The main end point was a clinical response at week 8. Secondary 
end points included a clinical response or remission with stop-
page of corticosteroids at week 30 in both studies and at week 
54 in ACT 1.
Of the 364 patients in ACT 1,   121 were given a placebo, 121 
received 5 mg of infliximab, and 122 to received 10 mg of inflix-
imab. Treatment was stopped early by 74 patients in the placebo 
group, 45 patients in the group receiving 5 mg of infliximab, and 
49 patients in the group getting 10 mg. Of the 364 patients in 
ACT 2, 123 were given a placebo, 121 received 5 mg of inflix-
imab, and 120 were administered 10 mg.  At week 8, in ACT 1, 
clinical remission was achieved in 69.4% of patients receiving 5 
mg of infliximab and 61.5 % of patients in the group receiving 
10 mg of infliximab. However, in the placebo group only 37.2 
percent of patients achieved clinical response. In ACT 2, at week 
8, 64.5 % of the patients in the group receiving 5 mg of infliximab 
and 69.2 % of patients receiving 10 mg of infliximab exhibited 
a clinical response, in comparison to the 29.3 % of patients in 
the placebo group.  Additionally, at the end of weeks 54 and 30 
significantly higher percentage of patients receiving Infliximab 
as opposed to the placebo went into complete remission and 
were able to discontinue the use of steroids (Rutgeers et al., 
2005).
Antibodies against Infliximab
A common concern when starting biologics is the possibility 
of a buildup of antibodies towards the drug.  One study tested 
serum samples from participants to check for a buildup of anti-
bodies to the drug. At week 54, 229 patients in ACT 1 had serum 
samples available for testing of antibody build up to Infliximab. Only 
14 patients had a positive test after the first infusion, 36 presented 
negative tests and 179 patients had inconclusive tests. In ACT 2 
from the 188 patients who had serum samples available for testing, 
12 presented a positive test for antibodies, 34 negative, and 142 in-
conclusive. Furthermore, in ACT 2 a clinical response still occurred 
in 11 patients who tested positive for antibodies.
The study further tested the safety of this drug. In both studies, 
the proportions of patients with adverse events were similar in 
the placebo group and the two Infliximab groups. In ACT 1, serious 
adverse events occurred in 25.6% of patients in the placebo group, 
21.5% of patients receiving 5 mg of Infliximab, and 23.8% percent 
of patients receiving 10 mg of infliximab. In ACT 2, the percent-
ages of serious adverse events were 19.5% in the placebo group, 
10.7% in the 5mg group, and 9.2% in the 10mg group. Based on 
these numbers, it was concluded that adverse events were more 
common in the placebo group showing that the medication was 
effective. Serious adverse events were most commonly related to 
the gastrointestinal system.
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Among adverse events in ACT 1, basal-cell carcinoma developed in 
one patient treated with 10 mg of infliximab. In ACT 2, basal-cell 
carcinoma developed in one patient who received placebo, and 
rectal adenocarcinoma developed in one patient treated with 5 
mg of infliximab. Three neurologic events occurred only in patients 
treated with infliximab. One patient in ACT 2 (receiving 5mg of 
infliximab) presented   a lupus-like reaction (Rutgeers et al.,2005).
The incidence of infections was similar among the groups in 
both studies. In ACT 1,   infections occurred in five patients in 
the placebo group, three patients in the group receiving 5 mg 
of infliximab, and eight patients in the group receiving 10 mg of 
infliximab. In ACT 2, severe infections occurred in one patient 
in the placebo group, two patients in the group receiving 5 mg 
of infliximab, and three patients in the group receiving 10 mg 
of Infliximab. In ACT 1, tuberculosis developed in one patient 
treated with 10 mg of infliximab (Rutgeers et al., 2005). 
This study proves that Infliximab is twice as likely two induce 
clinical remission in patients with moderate to severe ulcerative 
colitis in comparison to a placebo. Because the results of the 
study proved to be positive for adult patients put on Infliximab 
doctors wanted to use this drug to treat young children failing 
to respond to other medical therapy as well. Consequently, a 
study was done to test the safety and efficacy of the use of 
Remicade in pediatric patients with a moderate to severe form 
of the disease. A total of 60 pediatric patients ranging from ages 
6-17 years old who had active ulcerative colitis and had not re-
sponded to or tolerated other treatment options like immuno-
suppressants, steroids or 5ASA, were given 5 mg/ of infliximab 
at weeks 0, 2, and 6. The primary end point was response at 
week 8. At week 8, those whose responded well to the drug 
were randomly assigned to groups given Infliximab every 8 or 
12 weeks and were monitored through week 54 (Hyams et al., 
2012). 
Results
The study done proved Remicade to be highly effective in 
treating children with moderate to severe form of the disease. 
At week 8, Infliximab induced a response in 73.3% of patients. 
Additionally, 68.3% of patients achieved mucosal healing at week 
8. Those who achieved remission at week 8, were randomly as-
signed to receive Infliximab, 5mg every 8 weeks through week 
46 or every 12 weeks through week 42. At week 54, twice as 
many patients in the group that received Remicade every 8 
weeks achieved remission compared with the group that re-
ceived Remicade every 12 weeks.  Serious unfortunate events 
and infusion reactions occurred in comparable quantities in the 
8 and 12 week groups. No deaths, cancers, serious infections, 
or tuberculosis were reported in either group given Remicade. 
Infliximab was safe and effective, inducing a response at week 
8 in 73.3% of pediatric patients with moderate to severely ac-
tive ulcerative colitis who did not respond to other medical 
intervention. Those given the every 8 week infusion ended up 
with a higher clinical remission rate than those who were given 
infusion every 12 weeks (Hyams., 2012) . 
Today, Remicade is approved for children and adults. It is known 
to be one of the most effective methods of treatment for those 
suffering with an active state of the disease. Remicade is known 
to save people form undergoing a complete colectomy in addi-
tion to giving them a new lease on life. The studies above help 
strengthen this point showing how effective this biologic can be. 
Adalimumab
Another biologic on the rise is known as Humira has been ap-
proved by the FDA in 2012. Humira is a   treatment method 
for moderate to severe active ulcerative colitis in adult patients 
who have failed to respond to conventional therapy. Humira 
is a fully humanized monoclonal antibody against TNFa. Unlike 
Remicade, Humira is administered subcutaneously. Because 
Adalimumab is fairly new on the market it is still being test-
ed today. The main studies that assessed the effectiveness of 
Adalimumab in UC are the induction and maintenance trials, 
known as ULTRA 1 and ULTRA 2 (Ammuzi et al., 2013).
ULTRA 1 was an 8 week  randomized, double-blind, placebo 
controlled trial studying the use of Humira as an induction 
therapy in patients with moderate- severe UC despite the 
use of conventional therapy. In the ULTRA 1 trial 576 patients 
were randomly selected to receive either placebo or one of 
two different regimens of Adalimumab. The first regimen was 
160/80mg. patients were given 160mg at week  0 followed by 
80mg at week 2 and 40mg at weeks 4 and 6. The second regimen 
was   80/40mg. 80mg were given at week 0, 40mg were given at 
week 2, 4, 6. At the same time patients were still receiving stable 
treatment with oral corticoid steroids or immunosuppressants 
(Sandborn et al., 2013). 
The primary endpoint of the trail was clinical remission at week 
8. The patients who participated had moderately to severely 
active UC, with a Mayo score of 6–12 and simultaneous treat-
ment with at least oral corticosteroids, mercaptopurine/AZA 
or did not respond or could not endure prior corticosteroids 
or immunomodulators.
The primary endpoint of clinical remission was achieved with 
the higher dose of Adalimumab 160/80mg showing results of 
18.5% percent response and 9.2% placebo.  The amount of pa-
tients who achieved clinical remission at week 8 in the placebo 
group compared to the group receiving Humira at a regimen 
of 80/40mgand 80/40mg was a difference of point .6%. These 
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results show that Humira is much more effective when given 
to patients at a higher regimen. Additionally, Adalimumab treat-
ment was tolerated  well at both doses.  The safety profile was 
comparable to that of placebo. Ulcerative colitis was the most 
common adverse event which led to discontinuation of 4% of 
the placebo group, 3.8% of the 80/40mg group and 3.6% of the 
160/80mg group (Sandborn et al., 2013). 
ULTRA 2 was a 52 week study evaluating the efficacy of 
Humira as a maintenance therapy in UC patients. The ULTRA 
2 trial included 494 patients displaying moderate-severe ulcer-
ative colitis and failed to respond to conventional treatment. 
ULTRA 2 evaluated patients through week 52 but did not have 
an open-label phase after induction like in ULTRA 1.ULTRA 
2 included two treatment possibilities: 248 patients received 
Adalimumab 160/80mg (160 mg at week 0, 80 mg at week 2, 
and 40 mg every other week starting at week 4) and a placebo 
group consisting of 246 patients. Participants were randomly 
assigned to treatment groups. The two primary endpoints were 
remission at week 8 and 52 (Sandborn et al., 2013). 
Overall, clinical remission at week 8 was achieved in 16.5% of 
patients on Humira compared to 9.3% on placebo. The results 
for week 52 for the Adalimumab and placebo groups were 
17.3% and 8.5%. Secondary endpoints encompassed clinical 
response and mucosal healing.  The differences between adalim-
umab and placebo were substantial at weeks 8 and 52 in favor 
of adalimumab (Ammuzi et al., 2013).
A subclass analysis of ULTRA 2 evaluated the one-year main-
tenance outcomes in patients who responded to therapy with 
Adalimumab. Patients who attained clinical response at week 8 
were evaluated at week 52 to determine if they achieved several 
outcomes such as clinical remission, clinical response and muco-
sal healing. At week 8, approximately half of the Humira treated 
patients achieved clinical response. Of those, 30.9% from the 
placebo, 49.6% for the 160/80mg and 43.1% for the 80/40mg 
achieved clinical remission, clinical response and mucosal healing 
at week 52. Furthermore, of the week 8 responders who were 
dependent on corticosteroids, 21.1% achieved steroid-free re-
mission and 37.8%  were able to discontinue steroids at week 
52 (Sandborn et al., 2013).   
Aside from the ULTRA trials, there is further clinical experience 
on the use of Adalimumab for UC. Data from a study on a small 
group of 30 patients from Spain validated that Adalimumab in-
duction and maintenance therapy was effective in patients who 
previously failed other therapies including infliximab. At weeks 
4 and 12, clinical response was achieved in 16 (53%) and 18 
(60%) of patients, and clinical remission was achieved in 3(10%) 
and 8 (27%) of the patients. Adalimumab was continued in 50% 
of the patients after the 48week follow-up. Total colectomy was 
necessary in six (20%) of patients. Nevertheless, patients who 
reached clinical response at week 12 evaded colectomy over 
the long term (Denese et al., 2013). 
Adalimumab vs. Infliximab
Real-life data on the use of anti-TNF agents in UC was obtained 
from a Canadian group. This was a forthcoming study with a long-
term follow-up of 53 patients treated with either Remicade or 
Humira. Effectiveness was evaluated using physician’s worldwide 
assessment focusing on stabilization of bowel frequency, nonap-
pearance of blood with defecation and tapering of corticosteroids 
until it can be discontinued. Responses to induction therapy were 
96.4% for infliximab and 80% for Adalimumab. Responses to main-
tenance therapy were similar: infliximab 77.8% and Adalimumab 
70.0% (Denses et al.,2013).
Based on research present above, Remicade tends to produce bet-
ter results when given to patients with active disease. There haven’t 
been any studies found showing that Remicade does not induce 
remission to those experiencing moderate to severe ulcerative 
colitis. 
Administering biologics
However, due to the way the two biologics are administered may 
be enough of a reason for a patient to prefer one over the other. 
Remicade is administered as a 2-hour IV infusion so that it goes 
right into the bloodstream and starts to work. Doctors will nor-
mally give a patient 5mg per infusion. Some adult patients who at 
first respond to treatment or completely fail to respond to 5mg/kg 
may do well if their dose is increased to 10mg/kg.  Remicade is first 
given at weeks 0, 2, and 6.  Patients will then stay on maintenance 
therapy, which is every 8 weeks, which could be as few as 6times 
per year (REMICADE.com, 2014).  
Humira, on the other hand, is given via self-injection under the 
skin, typically every other week (after the initial starting doses). 
Humira needs to be kept in a refrigerator in its original bottle and 
protected from light until it’s ready to be used. The recommended 
dose regimen for adult patients taking Humira is 160 mg initially on 
Day 1 (given as four 40 mg injections in one day or as two 40 mg 
injections per day for two sequential days), followed by 80 mg two 
weeks later. When this is completed patients continue two weeks 
later with a dose of 40 mg every other week (HUMIRA.com, 2013).
Possible side effects
As always, all drugs come along with side effects. The usual side 
effects of biologics are nausea, headaches and fatigue. However, 
with time these side effects usually subside. More serious side ef-
fects have been experienced by patients especially those 65 years 
and older. Patients have had serious infections caused by viruses, 
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fungi or bacteria that have spread all through the body, including 
tuberculosis (TB) and histoplasmosis. Some of these infections 
have been deadly. Rare cancers have been reported in children and 
teenage patients taking TNF-blocker medicines. T-cell lymphoma, an 
uncommon form of deadly lymphoma, has transpired typically in 
teenage or young adult males with ulcerative colitis who were tak-
ing Remicade or Humira. (REMICADE.com, 2014; HUMIRA.com, 
2013). To help prevent serious side effects, patients are required to 
go for blood work initially every other week and then monthly in 
order to monitor their blood count. Though the side effects listed 
above are scary, a patient needs to weigh the benefits and the risks 
together. Prolonged, untreated inflammation is the number one 
cause of colon cancer a number one leading death in the United 
States today.
Immunosuppressants + Biologics
Seeing the results biologics produce on their own, doctors ques-
tioned if combining immunosuppressants with biologics to treat 
patients would have an even greater outcome than just using bio-
logics alone. Their thought process was as follows; the job of im-
munosuppressants is to stop the production of white blood cells 
by interfering with transcribing DNA and preventing the division 
and multiplying of many more white blood cells. Biologics on the 
other hand, are geared to stop an inflammatory response by bind-
ing with TNFa. Therefore, it was thought by combining these two 
drugs the likelihood of the patient achieving a remission is two 
times more likely than just treating them with one drug. 
Initial data is available from a UC study that had a similar de-
sign to SONIC (which was a study designed to test the same 
combination in Crohn’s patients) (Colombel et al., 2012).  The 
study included 239 patients with moderate-severe UC who 
were unexperienced to biologics, were failing corticosteroids 
and were either unexperienced to AZA or had stopped AZA 
three months before entering the study. Patients were randomly 
assigned to receive AZA 2.5 mg/kg, infliximab 5 mg/kg or inflix-
imab 5 mg/kg plus AZA 2.5 mg/kg for 16 weeks. The primary 
endpoint was steroid-free remission at week 16 and secondary 
endpoints included response and mucosal healing both at week 
16.  Preliminary results showed that the primary endpoint was 
achieved in the infliximab plus AZA group compared with the 
AZA alone. Additionally, infliximab plus AZA was greater to 
AZA or infliximab monotherapy in inducing steroid-free remis-
sion in patients. Patients treated with an infliximab plan of action 
were more likely to achieve response and mucosal healing than 
those treated with AZA monotherapy.  What does this study 
mean for anti-TNF therapy moving forward? It is tough to make 
any precise conclusions and more data is needed. Nonetheless, 
the limited data (only from infliximab experience) point that an-
ti-TNF therapy in combination with immunosuppressants may 
be more effective in early UC compared with monotherapy at 
16 weeks. Though remission is achieved in a greater percentage 
when the two classes of drugs are combined, it is not recom-
mended to combine the two because of increased risk of side 
effects (Denese et al., 2013). 
Conclusion
Recent advancement in bio-technology have thankfully led to 
the development of a large array of new therapeutic agents 
intended to target the exact site in the multifaceted cascade 
of cytokine and chemokine effector molecules involved in UC 
pathogenesis. In particular, the introduction of the chimeric 
monoclonal antibody to TNFa has deeply affected the clinical 
treatment of moderate to severe ulcerative colitis, opening the 
door to a new era in the treatment of this disease. Studies dis-
cussed in this paper show the effectiveness of both Remicade 
and Humira given to patients with an active state of this dis-
ease. Additionally, doctors tested the possibility of combining 
a biologic with an immunosupressent. Though remission nearly 
doubled, side effects were likely to double as well. Therefore, 
doctors are not pushing the combination of the two drugs un-
less there is no other option. 
With the recent introduction to biologics, patients suffering 
with ulcerative colitis in an unmanageable state are able to 
try a new treatment option with the hope of avoiding surgery. 
Remicade and Humira have both been proven to put patients 
with an active state of the disease into full remission.
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